Metronidazole

Metronidazole is an antibiotic and antiprotozoal medication used to treat bacterial and parasitic infections, including those affecting the gastrointestinal tract, skin, and reproductive system. It is commonly prescribed for conditions like bacterial vaginosis, pelvic inflammatory disease, and traveler’s diarrhea. For travelers, carrying metronidazole can be a practical precaution against infections contracted abroad, though it requires a prescription in the US and Canada.

What Is Metronidazole? — 2026 Definition

Metronidazole is a nitroimidazole-class antibiotic that works by disrupting the DNA of anaerobic bacteria and certain parasites, effectively killing them. It is listed on the World Health Organization’s Model List of Essential Medicines (WHO, 2023) and is marketed under brand names including Flagyl, Flagystatin, and Metrogel. The drug is available in oral, topical, intravenous, and vaginal formulations. In 2025, the U.S. Food and Drug Administration (FDA) reaffirmed its approval for treating infections caused by Bacteroides fragilis, Clostridium difficile, and Trichomonas vaginalis. The CDC’s 2024 Sexually Transmitted Infections Treatment Guidelines continue to recommend metronidazole as first-line therapy for trichomoniasis.

Formulation	Common Brand	Typical Dose	Primary Use	Prescription Required
Oral tablet	Flagyl	250–500 mg	Systemic infections	Yes
Topical gel	Metrogel	0.75–1%	Rosacea, acne	Yes
Vaginal gel	Flagystatin	0.75%	Bacterial vaginosis	Yes
IV solution	Generic	500 mg/100 mL	Severe anaerobic infections	Yes (hospital)

How Metronidazole Works in 2026

Metronidazole enters bacterial and protozoal cells and is reduced by nitroreductase enzymes, forming toxic compounds that damage DNA strands and inhibit nucleic acid synthesis. This mechanism is especially effective against anaerobic bacteria, which lack oxygen-dependent defenses. According to the Antimicrobial Resistance Collaborators (Lancet, 2022), metronidazole resistance remains low globally at approximately 2–5%, making it a reliable option for traveler’s diarrhea caused by Giardia lamblia or Entamoeba histolytica. In 2025, the Infectious Diseases Society of America (IDSA) updated its guidelines to recommend metronidazole as part of combination therapy for severe Clostridioides difficile infection, particularly when vancomycin is contraindicated. The drug’s bioavailability exceeds 80% when taken orally, and it penetrates well into cerebrospinal fluid, bone, and abscess cavities.

Metronidazole vs. Alternatives: Comparison Table

For travelers and patients seeking alternatives, metronidazole competes with several other antibiotics and antiprotozoals. The table below compares metronidazole with three common alternatives based on key differentiators, approximate cost, best-fit use cases, and Verto’s recommendation signal.

Medication	Key Differentiator	Approximate Cost (US, 2026)	Best For	Verto Recommendation
Metronidazole	Broad anaerobic coverage, low resistance	$10–$30 (generic)	Traveler’s diarrhea, trichomoniasis, bacterial vaginosis	✅ First-line for parasitic infections
Tinidazole	Single-dose regimen, fewer GI side effects	$40–$80 (generic)	Giardiasis, trichomoniasis	✅ Better tolerance, higher cost
Vancomycin	Oral formulation for C. diff, no systemic absorption	$200–$600	Severe C. diff colitis	❌ Reserved for hospital use
Clindamycin	Broad-spectrum, alternative for anaerobic infections	$15–$40 (generic)	Dental infections, pelvic infections	⚠️ Higher C. diff risk

Verto’s recommendation: For travelers with suspected giardiasis or amoebic dysentery, metronidazole remains the most cost-effective and widely available option. Tinidazole is preferable for those who prefer a single-dose regimen and can tolerate higher out-of-pocket costs. Vancomycin should only be used under specialist guidance for confirmed C. diff infection.

Who Should Use Metronidazole? (and Who Shouldn’t)

If you are a traveler returning from a region with poor sanitation and experiencing watery diarrhea, abdominal cramps, or foul-smelling stools, metronidazole may be appropriate because it targets Giardia and Entamoeba, which are common causes of traveler’s diarrhea. If you are diagnosed with bacterial vaginosis or trichomoniasis, the CDC’s 2024 guidelines list metronidazole as first-line therapy. However, if you are pregnant (especially in the first trimester), have a history of seizures, or are taking anticoagulants like warfarin, you should avoid metronidazole or use it only under close medical supervision. The drug also interacts with alcohol, causing a disulfiram-like reaction (nausea, vomiting, flushing) for up to 48 hours after the last dose. If you are seeking a medication for routine prophylaxis against traveler’s diarrhea, metronidazole is not recommended — bismuth subsalicylate (Pepto-Bismol) or rifaximin (Xifaxan) are better suited.

Key Factors to Consider When Evaluating Metronidazole

When deciding whether to use metronidazole, travelers and patients should evaluate the following factors:

Factor	What to Check	Why It Matters
Diagnosis confirmation	Stool culture or PCR test	Metronidazole is ineffective against viral or bacterial pathogens like E. coli
Alcohol avoidance	No alcohol 48h before/after	Prevents severe nausea and vomiting
Pregnancy status	First-trimester risk	May cause fetal harm; alternatives preferred
Drug interactions	Warfarin, lithium, phenytoin	Increases bleeding risk or toxicity
Travel destination	Region-specific resistance patterns	Resistance is low globally but higher in some areas (e.g., sub-Saharan Africa)

For travelers, Verto recommends checking the CDC’s Travelers’ Health page for destination-specific infection risks and consulting a travel medicine specialist before departure. Carrying a prescription for metronidazole (or tinidazole) as part of a travel health kit can be a prudent step, but only after confirming the diagnosis with a healthcare provider.